Skip to main content
Erschienen in: International Journal of Hematology 1/2011

01.01.2011 | Original Article

Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome

verfasst von: Naomi Ito-Habe, Hideo Wada, Takeshi Matsumoto, Kohshi Ohishi, Hidemi Toyoda, Eiji Ishikawa, Shinsuke Nomura, Yoshihiro Komada, Masaaki Ito, Tsutomu Nobori, Naoyuki Katayama

Erschienen in: International Journal of Hematology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Thrombotic microangiopathy (TMA) is associated with vascular endothelial cell injury and is sometimes linked with poor outcome. Von Willebrand factor (VWF) propeptide (VWFpp) is considered to be a marker of vascular endothelial cell injury. The plasma levels of VWF, VWFpp, and thrombomodulin (TM) were evaluated for their use in the diagnosis of TMA in 75 patients with TMA. There were 30 TMA patients with marked decreases in ADAMTS13 (TMA/ADAMTS13) and 45 without the decrease (TMA/other). The plasma levels of TM, VWF, and VWFpp values were significantly high in patients with TMA, especially TMA/other group. The plasma levels of TM and VWFpp were significantly high in non-survivor with TMA. In the TMA/other group, the plasma levels of VWFpp were negatively correlated with ADAMTS13 activity. The plasma levels of TM correlated with the renal function, but the plasma levels of VWFpp did not. A ROC analysis indicated that VWFpp and TM were useful markers for the prediction of a poor outcome. These findings suggest that VWFpp is an useful marker for the diagnosis of TMA and for the prediction of poor outcome.
Literatur
2.
Zurück zum Zitat Bukowski RM. Thrombotic thrombocytopenic purpura: a review. Rev Prog Hemost Thromb. 1982;6:287–337. Bukowski RM. Thrombotic thrombocytopenic purpura: a review. Rev Prog Hemost Thromb. 1982;6:287–337.
3.
Zurück zum Zitat Amorosi EL, Ultman JE. Thrombotic thrombocytopenic purpura: report of the 16 cases and review of the literature. Medicine. 1966;45:139–59.CrossRef Amorosi EL, Ultman JE. Thrombotic thrombocytopenic purpura: report of the 16 cases and review of the literature. Medicine. 1966;45:139–59.CrossRef
4.
Zurück zum Zitat Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T, Nozaki C. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the Von Willebrand factor-cleaving protease? J Biochem. 2001;130:475–80.PubMed Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T, Nozaki C. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the Von Willebrand factor-cleaving protease? J Biochem. 2001;130:475–80.PubMed
5.
Zurück zum Zitat Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpula. Nature. 2001;413:488–94.CrossRefPubMed Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpula. Nature. 2001;413:488–94.CrossRefPubMed
6.
Zurück zum Zitat Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of Von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–63.CrossRefPubMed Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of Von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–63.CrossRefPubMed
7.
Zurück zum Zitat Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving Von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223–34.PubMed Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving Von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223–34.PubMed
8.
Zurück zum Zitat Tsai H-M. Physiologic cleavage of Von Willebrand factor by a plasma protease is depend on its conformation and requires calcium ion. Blood. 1996;87:4235–44.PubMed Tsai H-M. Physiologic cleavage of Von Willebrand factor by a plasma protease is depend on its conformation and requires calcium ion. Blood. 1996;87:4235–44.PubMed
9.
Zurück zum Zitat Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129:93–100.CrossRefPubMed Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129:93–100.CrossRefPubMed
10.
Zurück zum Zitat Kobayashi T, Wada H, Kamikura Y, Matsumoto T, Mori Y, Kaneko T, Nobori T, Matsumoto M, Fujimura Y, Shiku H. Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura. Thromb Res. 2007;119:447–52.CrossRefPubMed Kobayashi T, Wada H, Kamikura Y, Matsumoto T, Mori Y, Kaneko T, Nobori T, Matsumoto M, Fujimura Y, Shiku H. Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura. Thromb Res. 2007;119:447–52.CrossRefPubMed
11.
12.
Zurück zum Zitat Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of Von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-d-vasopressin in humans. Blood. 1996;88:2951–8.PubMed Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of Von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-d-vasopressin in humans. Blood. 1996;88:2951–8.PubMed
13.
Zurück zum Zitat Federici AB. VWF propeptide: a useful marker in VWD. Blood. 2006;108:3229–30.CrossRef Federici AB. VWF propeptide: a useful marker in VWD. Blood. 2006;108:3229–30.CrossRef
14.
Zurück zum Zitat Wada H, Ohiwa M, Kaneko T, Tamaki S, Tanigawa M, Shirakawa S, Koyama M, Hayashi T, Suzuki K. Plasma Thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol. 1992;39:20–4.CrossRefPubMed Wada H, Ohiwa M, Kaneko T, Tamaki S, Tanigawa M, Shirakawa S, Koyama M, Hayashi T, Suzuki K. Plasma Thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol. 1992;39:20–4.CrossRefPubMed
15.
Zurück zum Zitat Wada H, Kaneko T, Ohiwa M, Tanigawa M, Hayashi T, Tamaki S, Minami N, Deguchi Katsumi, Suzuki K, Nakano T, Shirakawa S. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol. 1993;44:101–5.CrossRefPubMed Wada H, Kaneko T, Ohiwa M, Tanigawa M, Hayashi T, Tamaki S, Minami N, Deguchi Katsumi, Suzuki K, Nakano T, Shirakawa S. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol. 1993;44:101–5.CrossRefPubMed
16.
Zurück zum Zitat Mori Y, Wada H, Gabazza EC, Minami N, Nobori T, Shiku H, Yagi H, Ishizashi H, Matsumoto M, Fujimura Y. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion. 2002;42:572–80.CrossRefPubMed Mori Y, Wada H, Gabazza EC, Minami N, Nobori T, Shiku H, Yagi H, Ishizashi H, Matsumoto M, Fujimura Y. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion. 2002;42:572–80.CrossRefPubMed
17.
Zurück zum Zitat Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500–11.CrossRefPubMed Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500–11.CrossRefPubMed
18.
Zurück zum Zitat Ito N, Wada H, Matsumoto M, Fujimura Y, Murata M, Izuno T, Sugita M, Ikeda Y. National questionnaire survey of TMA. Int J Hematol. 2009;90:328–35.CrossRefPubMed Ito N, Wada H, Matsumoto M, Fujimura Y, Murata M, Izuno T, Sugita M, Ikeda Y. National questionnaire survey of TMA. Int J Hematol. 2009;90:328–35.CrossRefPubMed
19.
Zurück zum Zitat Ito-Habe N, Wada H, Matsumoto M, Fujimura Y, Murata M, Izuno T, Sugita M, Ikeda Y. A second national questionnaire survey of TMA. Int J Hematol. 2010;92:68–75.CrossRefPubMed Ito-Habe N, Wada H, Matsumoto M, Fujimura Y, Murata M, Izuno T, Sugita M, Ikeda Y. A second national questionnaire survey of TMA. Int J Hematol. 2010;92:68–75.CrossRefPubMed
20.
Zurück zum Zitat Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Seminar Hematol. 2004;41:68–74.CrossRef Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Seminar Hematol. 2004;41:68–74.CrossRef
21.
Zurück zum Zitat Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998–2008. Intern Med. 2010;49:7–15.CrossRefPubMed Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998–2008. Intern Med. 2010;49:7–15.CrossRefPubMed
22.
Zurück zum Zitat Lian EC. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond. Semin Thromb Hemost. 2005;31:625–32.CrossRefPubMed Lian EC. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond. Semin Thromb Hemost. 2005;31:625–32.CrossRefPubMed
23.
Zurück zum Zitat Kremer Hovinga JA, Zeerleder S, Kessler P, Romani de Wit T, van Mourik JA, Hack CE, ten Cate H, Reitsma PH, Wuillemin WA, Lämmle B. ADAMTS-13, Von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost. 2007;5:2284–90.CrossRefPubMed Kremer Hovinga JA, Zeerleder S, Kessler P, Romani de Wit T, van Mourik JA, Hack CE, ten Cate H, Reitsma PH, Wuillemin WA, Lämmle B. ADAMTS-13, Von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost. 2007;5:2284–90.CrossRefPubMed
24.
Zurück zum Zitat Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y. Severe secondary deficiency of Von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006;107:528–34.CrossRefPubMed Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y. Severe secondary deficiency of Von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006;107:528–34.CrossRefPubMed
Metadaten
Titel
Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome
verfasst von
Naomi Ito-Habe
Hideo Wada
Takeshi Matsumoto
Kohshi Ohishi
Hidemi Toyoda
Eiji Ishikawa
Shinsuke Nomura
Yoshihiro Komada
Masaaki Ito
Tsutomu Nobori
Naoyuki Katayama
Publikationsdatum
01.01.2011
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 1/2011
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0732-4

Weitere Artikel der Ausgabe 1/2011

International Journal of Hematology 1/2011 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.